Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands
- PMID: 17497839
- PMCID: PMC2669435
- DOI: 10.1021/jm061238m
Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands
Abstract
Endomorphin-2 (H-Tyr-Pro-Phe-Phe-NH2) and [Dmt1]EM-2 (Dmt = 2',6'-dimethyl-l-tyrosine) analogues, containing alkylated Phe3 derivatives, 2'-monomethyl (2, 2'), 3',5'- and 2',6'-dimethyl (3, 3', and 4', respectively), 2',4',6'-trimethyl (6, 6'), 2'-ethyl-6'-methyl (7, 7'), and 2'-isopropyl-6'-methyl (8, 8') groups or Dmt (5, 5'), had the following characteristics: (i) [Xaa3]EM-2 analogues exhibited improved mu- and delta-opioid receptor affinities. The latter, however, were inconsequential (Kidelta = 491-3451 nM). (ii) [Dmt1,Xaa3]EM-2 analogues enhanced mu- and delta-opioid receptor affinities (Kimu = 0.069-0.32 nM; Kidelta = 1.83-99.8 nM) without kappa-opioid receptor interaction. (iii) There were elevated mu-bioactivity (IC50 = 0.12-14.4 nM) and abolished delta-agonism (IC50 > 10 muM in 2', 3', 4', 5', 6'), although 4' and 6' demonstrated a potent mixed mu-agonism/delta-antagonism (for 4', IC50mu = 0.12 and pA2 = 8.15; for 6', IC50mu = 0.21 nM and pA2 = 9.05) and 7' was a dual mu-agonist/delta-agonist (IC50mu = 0.17 nM; IC50delta = 0.51 nM).
Figures
Similar articles
-
Engineering endomorphin drugs: state of the art.Expert Opin Ther Pat. 2012 Jan;22(1):1-14. doi: 10.1517/13543776.2012.646261. Epub 2012 Jan 4. Expert Opin Ther Pat. 2012. PMID: 22214283 Free PMC article. Review.
-
Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.J Med Chem. 2004 Jul 1;47(14):3591-9. doi: 10.1021/jm030649p. J Med Chem. 2004. PMID: 15214786
-
Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.J Med Chem. 2005 Jan 27;48(2):586-92. doi: 10.1021/jm049384k. J Med Chem. 2005. PMID: 15658871
-
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.J Med Chem. 2002 Jan 31;45(3):713-20. doi: 10.1021/jm010449i. J Med Chem. 2002. PMID: 11806723
-
Developmental potential for endomorphin opioidmimetic drugs.Int J Med Chem. 2012;2012:715123. doi: 10.1155/2012/715123. Epub 2012 Jun 15. Int J Med Chem. 2012. PMID: 25954530 Free PMC article. Review.
Cited by
-
Engineering endomorphin drugs: state of the art.Expert Opin Ther Pat. 2012 Jan;22(1):1-14. doi: 10.1517/13543776.2012.646261. Epub 2012 Jan 4. Expert Opin Ther Pat. 2012. PMID: 22214283 Free PMC article. Review.
-
Divergent Cl- and H+ pathways underlie transport coupling and gating in CLC exchangers and channels.Elife. 2020 Apr 28;9:e51224. doi: 10.7554/eLife.51224. Elife. 2020. PMID: 32343228 Free PMC article.
-
A Biased View of μ-Opioid Receptors?Mol Pharmacol. 2019 Nov;96(5):542-549. doi: 10.1124/mol.119.115956. Epub 2019 Jun 7. Mol Pharmacol. 2019. PMID: 31175184 Free PMC article. Review.
-
Molecular Pharmacology of δ-Opioid Receptors.Pharmacol Rev. 2016 Jul;68(3):631-700. doi: 10.1124/pr.114.008979. Pharmacol Rev. 2016. PMID: 27343248 Free PMC article. Review.
-
Bi- or multifunctional opioid peptide drugs.Life Sci. 2010 Apr 10;86(15-16):598-603. doi: 10.1016/j.lfs.2009.02.025. Epub 2009 Mar 11. Life Sci. 2010. PMID: 19285088 Free PMC article. Review.
References
-
- Zadina JE, Hackler L, Ge LJ, Kastin AJ. A Potent and selective endogenous agonist for the mu-opiate receptor. Nature. 1997;386:499–502. - PubMed
-
- Wilson AM, Soignier RD, Zadina JE, Kastin AJ, Nores WL, Olson RD, Olson GA. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides. 2000;21:1871–1874. - PubMed
-
- Carrigan KA, Nelson CJ, Lysle DT. Endomorphin-1 induces antinociception without immunomodulatory effects in the rat. Psychopharmacology. 2000;151:299–305. - PubMed
-
- Harrison LM, Kastin AJ, Zadina JE. Differential effects of endomorphin-1,endomorphin-2, and Tyr-W-MIF-1 on activation of G-proteins in SH-SY5Y human neuroblastoma membranes. Peptides. 1998;19:749–753. - PubMed
-
- Kakizawa K, Shimohira I, Sakurada S, Fujimura T, Murayama K, Ueda H. Parallel stimulations of in vitro and in situ [35S]GTPγS binding by endomorphin 1 and DAMGO in mouse brains. Peptides. 1998;19:755–758. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials